Canine presumed glial brain tumours treated with radiotherapy: Is there an inferior outcome in tumours contacting the subventricular zone?
brain tumour
dog
drop metastasis
glioma
neuroepithelial tumours
radiation therapy
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
21
04
2021
received:
30
12
2020
accepted:
21
04
2021
pubmed:
27
4
2021
medline:
1
4
2022
entrez:
26
4
2021
Statut:
ppublish
Résumé
Post-treatment outcome in canine glial tumours is described with a broad range of survival times between 2 and 28 months. After surgery or radiation therapy, the tumours may progress locally or spread within the central nervous system. It is unknown if tumour- or patient-specific factors influence prognosis. In humans, glioblastoma involving the subventricular zone has been found to recur distantly, with shortened time to progression and overall survival. We included 32 dogs irradiated for a presumptive primary glial brain tumour in this retrospective cohort study. Tumours were grouped relative to subventricular zone contact and overt ventricular invasion assessing pre-treatment magnetic resonance images. Median time to progression (TTP) for all cases was 534 days (95%CI, 310-758), with a significantly shorter TTP in dogs with lesions at the subventricular zone (median TTP, 260 vs. 687 days; p = .049). Tumours at the subventricular zone progressed more often (p = .001), and more likely as CNS-metastasis (52.9% vs. 13.3%, p = .028). Median overall survival (OS) was 489 days (95%CI, 147-831) and median tumour-specific survival 609 days (95%CI, 382-835). Involvement of the subventricular zone was significantly associated with a shorter tumour-specific survival (median, 306 vs. 719 days; p = .044). Glial tumours contacting the subventricular zone in dogs have a shorter tumour-specific survival and a higher rate of progression and CNS-metastasis. Despite local tumour control, metastasis must be considered and should prompt further treatment approaches.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-37Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Hu H, Barker A, Harcourt-Brown T, Jeffery N. Systematic review of brain tumor treatment in dogs. J Vet Intern Med. 2015;29(6):1456-1463.
Rossmeisl JH, Pancotto TE. Tumors of the nervous system. In: Vail T, Liptak J, ed. Small Animal Clinical Oncology. 6th ed. St. Louris, Missouri: Elsevier Inc.; 2020:657-674.
Miller AD, Miller CR, Rossmeisl JH. Canine primary intracranial cancer: a Clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors. Front Oncol. 2019;9:1151.
Debreuque M, De Fornel P, David I, et al. Definitive-intent uniform megavoltage fractioned radiotherapy protocol for presumed canine intracranial gliomas: retrospective analysis of survival and prognostic factors in 38 cases (2013-2019). BMC Vet Res. 2020;16(1):412.
Dolera M, Malfassi L, Bianchi C, et al. Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. Vet Comp Oncol. 2018;16(1):90-101.
Schwarz P, Meier V, Soukup A, et al. Comparative evaluation of a novel, moderately hypofractionated radiation protocol in 56 dogs with symptomatic intracranial neoplasia. J Vet Intern Med. 2018;32(6):2013-2020.
MacLellan JD, Arnold SA, Dave AC, Hunt MA, Pluhar GE. Association of magnetic resonance imaging-based preoperative tumor volume with postsurgical survival time in dogs with primary intracranial glioma. J Am Vet Med Assoc. 2018;252(1):98-102.
Sunol A, Mascort J, Font C, Bastante AR, Pumarola M, Feliu-Pascual AL. Long-term follow-up of surgical resection alone for primary intracranial rostrotentorial tumors in dogs: 29 cases (2002-2013). Open Vet J. 2017;7(4):375-383.
Hubbard ME, Arnold S, Bin Zahid A, et al. Naturally occurring canine glioma as a model for novel therapeutics. Cancer Invest. 2018;36(8):415-423.
Kani Y, Cecere TE, Lahmers K, et al. Diagnostic accuracy of stereotactic brain biopsy for intracranial neoplasia in dogs: comparison of biopsy, surgical resection, and necropsy specimens. J Vet Intern Med. 2019;33(3):1384-1391.
Koehler JW, Miller AD, Miller CR, et al. A revised diagnostic classification of canine glioma: towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma. J Neuropathol Exp Neurol. 2018;77(11):1039-1054.
Lim DA, Cha S, Mayo MC, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007;9(4):424-429.
Nourallah B, Digpal R, Jena R, Watts C. Irradiating the subventricular zone in glioblastoma patients: is there a case for a clinical trial? Clin Oncol (R Coll Radiol). 2017;29(1):26-33.
Smith AW, Mehta MP, Wernicke AG. Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. J Neurooncol. 2016;128(2):207-216.
Bentley RT, Ober CP, Anderson KL, et al. Canine intracranial gliomas: relationship between magnetic resonance imaging criteria and tumor type and grade. Vet J. 2013;198(2):463-471.
Young BD, Levine JM, Porter BF, et al. Magnetic resonance imaging features of intracranial astrocytomas and oligodendrogliomas in dogs. Vet Radiol Ultrasound. 2011;52(2):132-141.
Fernandez-Flores F, Garcia-Verdugo JM, Martin-Ibanez R, et al. Characterization of the canine rostral ventricular-subventricular zone: morphological, immunohistochemical, ultrastructural, and neurosphere assay studies. J Comp Neurol. 2018;526(4):721-741.
Packer RA, Rossmeisl JH, Kent MS, Griffin JF, Mazcko C, LeBlanc AK. Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials. Vet Radiol Ultrasound. 2018;59(3):261-271.
Julia-Sape M, Acosta D, Majos C, et al. Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg. 2006;105(1):6-14.
Rohrer Bley C, Meier V, Schwarz P, Roos M, Besserer J. A complication probability planning study to predict the safety of a new protocol for intracranial tumour radiotherapy in dogs. Vet Comp Oncol. 2017;15(4):1295-1308.
Schwarz P, Meier V, Soukup A, et al. Comparative evaluation of a novel, moderately hypofractionated radiation protocol in 56 dogs with symptomatic intracranial neoplasia. J Vet Intern Med. 2018;32(6):2013-2020.
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50). In. Bethesda, MD, 1993.
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 62, Supplement to ICRU Report 50). In. Bethesda, MD, 1999.
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT) (Report 83). In. Oxford University Press, Oxford, 2010.
Rohrer Bley C, Meier VS, Besserer J, Schneider U. Intensity-modulated radiation therapy dose prescription and reporting: sum and substance of the international commission on radiation units and measurements report 83 for veterinary medicine. Vet Radiol Ultrasound. 2019;60(3):255-264.
Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176-183.
Bhatti SF, De Risio L, Munana K, et al. International veterinary epilepsy task force consensus proposal: medical treatment of canine epilepsy in Europe. BMC Vet Res. 2015;11:176.
Vigeral M, Bentley RT, Rancilio NJ, Miller MA, Heng HG. Imaging diagnosis -Antemortem detection of Oligodendroglioma "cerebrospinal fluid drop metastases" in a dog by serial magnetic resonance imaging. Vet Radiol Ultrasound. 2018;59(4):E32-E37.
Qi XT, Zhan JS, Xiao LM, et al. The unwanted cell migration in the brain: glioma metastasis. Neurochem Res. 2017;42(6):1847-1863.
Ortensi B, Setti M, Osti D, Pelicci G. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther. 2013;4(1):18.
Quinones-Hinojosa A, Chaichana K. The human subventricular zone: a source of new cells and a potential source of brain tumors. Exp Neurol. 2007;205(2):313-324.
Elefante A, Peca C, Del Basso De Caro ML, et al. Symptomatic spinal cord metastasis from cerebral oligodendroglioma. Neurol Sci. 2012;33(3):609-613.
Lawton CD, Nagasawa DT, Yang I, Fessler RG, Smith ZA. Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease. J Neurosurg Spine. 2012;17(5):438-448.
Keyerleber MA, McEntee MC, Farrelly J, Thompson MS, Scrivani PV, Dewey CW. Three-dimensional conformal radiation therapy alone or in combination with surgery for treatment of canine intracranial meningiomas. Vet Comp Oncol. 2015;13(4):385-397.
Rohrer Bley C, Sumova A, Roos M, Kaser-Hotz B. Irradiation of brain tumors in dogs with neurologic disease. J Vet Intern Med. 2005;19(6):849-854.
Treggiari E, Maddox TW, Goncalves R, Benoit J, Buchholz J, Blackwood L. Retrospective comparison of three-dimensional conformal radiation therapy vs. prednisolone alone in 30 cases of canine Infratentorial brain tumors. Vet Radiol Ultrasound. 2017;58(1):106-116.
Rodenas S, Pumarola M, Gaitero L, Zamora A, Anor S. Magnetic resonance imaging findings in 40 dogs with histologically confirmed intracranial tumours. Vet J. 2011;187(1):85-91.
Bentley RT. Magnetic resonance imaging diagnosis of brain tumors in dogs. Vet J. 2015;205(2):204-216.
Wisner ER, Dickinson PJ, Higgins RJ. Magnetic resonance imaging features of canine intracranial neoplasia. Vet Radiol Ultrasound. 2011;52(Suppl 1):S52-S61.
Filley A, Henriquez M, Bhowmik T, et al. Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol. 2018;137(3):469-479.
Herranz C, Fernandez F, Martin-Ibanez R, et al. Spontaneously arising canine glioma as a potential model for human glioma. J Comp Pathol. 2016;154(2-3):169-179.
Nam JY, de Groot JF. Treatment of glioblastoma. J Oncol Pract. 2017;13(10):629-638.
Van Meervenne S, Verhoeven PS, de Vos J, Gielen IM, Polis I, Van Ham LM. Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions. Vet Comp Oncol. 2014;12(1):67-77.
Moirano SJ, Dewey CW, Wright KZ, Cohen PW. Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: a comparative retrospective study (2008-2017). Vet Comp Oncol. 2018;16(4):459-466.
Marconato L, Bley CR, Leone V, Finotello R. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer. Vet Comp Oncol. 2020;18:838-842.
Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther. 2002;40(8):354-367.
Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198-210.
Perazzoli G, Prados J, Ortiz R, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One. 2015;10(10):e0140131.
Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25(12):1470-1475.
Eoli M, Menghi F, Bruzzone MG, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007;13(9):2606-2613.
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.